Awakn’s Head Of Ketamine Therapy Celia Morgan Named Influential Woman In Psychedelics

What makes one an influential woman in psychedelics? For Celia Morgan, it’s been her longstanding commitment to understanding the effects of ketamine and how it can fit into a therapeutic setting.

Morgan, a ketamine researcher and the head of ketamine-assisted therapy at Awakn Life Sciences (NEO: AWKN)(OTCMKTS: AWKNF), was named one of the most influential women shaping the future of the psychedelics industry in a recent Business Insider article.

Last week The Dales Report sat down with her to discuss her work on ketamine, her role at Awakn, and how Awakn’s KARE Program (that is, Ketamine in the Reduction of Alcohol Relapse), was developed to help people reduce their reliance on and consumption of alcohol.

Morgan began working on ketamine more than 20 years ago during her undergraduate degree.

“What fascinated me about ketamine and psychedelics in general was their ability to change your conscious experience,” she says.

At Awakn, the KARE Program came out of a phase two trial that was funded by the UK government, where ketamine was combined with a psychological therapy. 

In the trial, Morgan and team compared the effects of different treatments—ketamine combined with therapy, ketamine on its own, a placebo combined therapy, and a placebo with basic alcohol education—to find out which would be more efficacious.

Participants in the therapy groups received seven psychotherapy sessions, which incorporated aspects of mindfulness and cognitive behavior therapy, and three ketamine sessions.

“What we found was dramatic reduction in drinking in the group given ketamine and therapy, with the greatest effects in that group,” said Morgan. The next most effective treatment was ketamine on its own, followed by the placebo/therapy combination, while the placebo/alcohol education combination was the least effective in reducing drinking.

Morgan pointed out that based on trial data, people who were abstinent only 2 percent of time before the trial were abstinent 86 percent of time at the trial’s six-month follow-up mark—translating to huge decreases in mortality: “Before the study,  1 in 8 of our patients would have died prematurely because of drinking,” she says. “Now it’s 1 in 80.”

The study is being followed up with a phase 3 trial led by Awakn.  

Hear more about Awakn’s work on ketamine and alcoholism from Morgan in the video interview above. 

__________

* In accordance with an executed agreement between The Dales Report and Awakn Life Sciences, The Dales Report is engaged with the aforementioned on a current 4-month contract and has received 125,000 common shares for services rendered included in the agreement, with the purpose of publicly disseminating information pertaining to Awakn Life Sciences via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer .